A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India

CompletedOBSERVATIONAL

Enrollment

1,386

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

liraglutide

Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.

Trial Locations (1)

Novo Nordisk Investigational Site, Bangalore